Several hypotheses that may explain impaired p53 pathway activity in p53 wild-type melanoma have been proposed, including mutations of CDKN2A (encoding p14ARF, which inhibits p53 degradation by HDM2) and overexpression of HDM2 (human double minute 2) or anti-apoptotic proteins (iASPP and BCL-2) [7]. This evidence concerns the gene CDKN2A and melanoma.